Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05302583 · ClinicalTrials.gov registry record · NA
Aromatherapy Inhaler Use for HSCT Distress
A NA study of Hematopoetic Stem Cell Transplant and Cancer Distress, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05302583 is a NA study of Hematopoetic Stem Cell Transplant and Cancer Distress that is actively recruiting participants, run by Stanford University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05302583, a NA study of Hematopoetic Stem Cell Transplant and Cancer Distress, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).
Conditions Studied
Interventions
- OTHER Aromatherapy Inhaler
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05302583
The ClinicalTrials.gov registry entry for NCT05302583 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hematopoetic Stem Cell Transplant appearing as the primary indexed condition, and to 1 intervention - of which Aromatherapy Inhaler is the first listed.
NCT05302583 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05302583 about?
NCT05302583 is a clinical study titled "Aromatherapy Inhaler Use for HSCT Distress". The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).
What is the current status of trial NCT05302583?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-06-16. Estimated completion is 2026-03.
What conditions does trial NCT05302583 study?
This clinical trial studies the following conditions: Hematopoetic Stem Cell Transplant, Cancer Distress, Cancer Coping, Aromatherapy.
What interventions are being tested in trial NCT05302583?
The interventions under investigation include: Aromatherapy Inhaler (OTHER).
Who is sponsoring clinical trial NCT05302583?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05302583 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoetic Stem Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.